Nic Johnson News Today

over. >> the case goes back to the fifth circuit and could go on for months or even years before we get final disposition. >> this all started last november when the conservative group alliance defending freedom filed a lawsuit in texas challenging the fda is original for approval of the drug that happened 23 years ago. and april 7th the texas-based us district judge then ruled in their favor revoking the fdas approval, saying it went above its authority when it approved mifepristone b...

Good morning, everybody. It is tuesday, february 19, im Yasmin Vossoughian alongside a louis burgdorf. Well start with deputy ag, Rod Rosenstein who spent the last 21 months overseeing the special counsels investigation has aboutat three weeks left at the Justice Department. Officials put Rod Rosensteins date of departure around the middle ofnd march after a brief transition period under new attorney general william barr. Reportsli indicate that barr settled on deputy transportation secretary Je...

Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024 LONDON, April 25, 2024 /PRNewswire/ --...

Next-generation cell therapies to target chronic diseasesHOUSTON, April 25, 2024 -- FibroBiologics, Inc., and Charles River Laboratories , a highly respected, global provider of drug discovery,...

BETHESDA, Md., April 24, 2024 -- Gain Therapeutics, Inc. , a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule...

BETHESDA, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...

BETHESDA, Md., April 08, 2024 -- Gain Therapeutics, Inc. , a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule...

BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...

BETHESDA, Md., April 01, 2024 -- Gain Therapeutics, Inc. , a clinical-stage biotechnology company leading the discovery and development of the next generation allosteric small molecule therapies,...

BETHESDA, Md., April 01, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation